PDF(Pubmed)
Abstract：
UNASSIGNED: Diagnosing and treating lameness in horses is essential to improving their welfare. In equine orthopedic practice, infrared thermography (IRT) can indirectly detect soreness. Non-steroidal anti-inflammatory drugs can treat painful and inflammatory processes in horses. Using IRT, the efficacy of meloxicam (Maxicam Gel®) was evaluated in pre-treating transient synovitis in horses induced by a middle carpal joint injection of lipopolysaccharides (LPS) from E. coli 055:B5 at a dose of 10 endotoxin units.
UNASSIGNED: In a cross-over design, six healthy horses were randomly assigned to receive either 0.6 mg/kg of oral Maxicam Gel® (MAXVO) or a mock administration (control group, C) following a two-week washout period. IRT of the middle carpal joint, visual lameness assessment and joint circumference were recorded over time. Clinical and hematological evaluations were performed. Synovial fluid aspirates were analyzed for total nucleated cell count, total protein, and prostaglandin E2. A mixed effects analysis of variance was performed for repeated measures over time, followed by Tukey\'s test. A multinomial logistic regression was conducted to determine whether there is a relationship between a thermography temperature change and the lameness score.
UNASSIGNED: There were no changes in joint circumference. The MAXVO group showed a lower rectal temperature 4 h after synovitis induction. The C group presented an increase in neutrophils and a decrease in total hemoglobin and hematocrit 8 h after induction. No changes were observed in the synovial fluid between groups. The horses that received meloxicam did not show clinically significant lameness at any time, while the C group showed an increase in lameness 2, 4, and 8 h after synovitis induction.
UNASSIGNED: IRT indicated that the skin surface temperature of the middle carpal joint was lower in horses who received meloxicam, suggesting a reduction in the inflammatory process induced by LPS. It was observed that the maximum temperature peaks in the dorsopalmar and lateropalmar positions can be utilized to predict the severity of lameness, particularly when the temperature rises above 34°C. Horses pre-treated with meloxicam showed either reduced or no indication of mild to moderate pain and presented a lowehr thermographic temperature, which indicates the effectiveness of Maxicam Gel® as an anti-inflammatory.
UNASSIGNED: In a cross-over design, six healthy horses were randomly assigned to receive either 0.6 mg/kg of oral Maxicam Gel® (MAXVO) or a mock administration (control group, C) following a two-week washout period. IRT of the middle carpal joint, visual lameness assessment and joint circumference were recorded over time. Clinical and hematological evaluations were performed. Synovial fluid aspirates were analyzed for total nucleated cell count, total protein, and prostaglandin E2. A mixed effects analysis of variance was performed for repeated measures over time, followed by Tukey\'s test. A multinomial logistic regression was conducted to determine whether there is a relationship between a thermography temperature change and the lameness score.
UNASSIGNED: There were no changes in joint circumference. The MAXVO group showed a lower rectal temperature 4 h after synovitis induction. The C group presented an increase in neutrophils and a decrease in total hemoglobin and hematocrit 8 h after induction. No changes were observed in the synovial fluid between groups. The horses that received meloxicam did not show clinically significant lameness at any time, while the C group showed an increase in lameness 2, 4, and 8 h after synovitis induction.
UNASSIGNED: IRT indicated that the skin surface temperature of the middle carpal joint was lower in horses who received meloxicam, suggesting a reduction in the inflammatory process induced by LPS. It was observed that the maximum temperature peaks in the dorsopalmar and lateropalmar positions can be utilized to predict the severity of lameness, particularly when the temperature rises above 34°C. Horses pre-treated with meloxicam showed either reduced or no indication of mild to moderate pain and presented a lowehr thermographic temperature, which indicates the effectiveness of Maxicam Gel® as an anti-inflammatory.
摘要：
■诊断和治疗马匹的跛行对于改善其福利至关重要。在马矫形实践中，红外热成像（IRT）可以间接检测酸痛。非甾体抗炎药可以治疗马的疼痛和炎症过程。使用IRT,评估了美洛昔康(MaxicamGel®)对10内毒素单位剂量的大肠杆菌055:B5中腕关节注射脂多糖(LPS)诱导的马短暂性滑膜炎的预处理效果.
■在交叉设计中，六匹健康马匹被随机分配接受0.6mg/kg口服MaxicamGel®（MAXVO）或模拟给药（对照组，C)经过两周的冲洗期。腕关节中部的IRT，随着时间的推移,我们记录了视觉跛行评估和关节周长.进行临床和血液学评估。分析滑液抽吸物的总有核细胞计数，总蛋白质，和前列腺素E2.随着时间的推移，对重复测量进行了混合效应方差分析，其次是Tukey\的测试。进行多项逻辑回归以确定热成像温度变化与跛行评分之间是否存在关系。
■关节周长没有变化。在滑膜炎诱导后4小时，MAXVO组显示出更低的直肠温度。诱导后8小时，C组中性粒细胞增加，总血红蛋白和血细胞比容降低。组间滑液无变化。接受美洛昔康的马匹在任何时候都没有表现出临床上明显的跛行，而C组滑膜炎诱导后2、4和8小时的跛行增加。
■IRT表明接受美洛昔康的马的中腕关节的皮肤表面温度较低，提示LPS诱导的炎症过程减少。据观察，背脊和背脊位置的最高温度峰值可用于预测跛行的严重程度，特别是当温度上升到34℃以上时。用美洛昔康预处理的马显示出轻度至中度疼痛的减少或没有迹象，并且呈现低温图温度，这表明Maxicam凝胶®作为抗炎的有效性。
■在交叉设计中，六匹健康马匹被随机分配接受0.6mg/kg口服MaxicamGel®（MAXVO）或模拟给药（对照组，C)经过两周的冲洗期。腕关节中部的IRT，随着时间的推移,我们记录了视觉跛行评估和关节周长.进行临床和血液学评估。分析滑液抽吸物的总有核细胞计数，总蛋白质，和前列腺素E2.随着时间的推移，对重复测量进行了混合效应方差分析，其次是Tukey\的测试。进行多项逻辑回归以确定热成像温度变化与跛行评分之间是否存在关系。
■关节周长没有变化。在滑膜炎诱导后4小时，MAXVO组显示出更低的直肠温度。诱导后8小时，C组中性粒细胞增加，总血红蛋白和血细胞比容降低。组间滑液无变化。接受美洛昔康的马匹在任何时候都没有表现出临床上明显的跛行，而C组滑膜炎诱导后2、4和8小时的跛行增加。
■IRT表明接受美洛昔康的马的中腕关节的皮肤表面温度较低，提示LPS诱导的炎症过程减少。据观察，背脊和背脊位置的最高温度峰值可用于预测跛行的严重程度，特别是当温度上升到34℃以上时。用美洛昔康预处理的马显示出轻度至中度疼痛的减少或没有迹象，并且呈现低温图温度，这表明Maxicam凝胶®作为抗炎的有效性。
